XP 004
Alternative Names: XP-004Latest Information Update: 26 Jul 2024
At a glance
- Originator Shanghai Xinpu BioTechnology Company
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pancreatic cancer
Most Recent Events
- 01 Apr 2024 Phase-I clinical trials in Pancreatic cancer (Adjuvant therapy, Second-line therapy or greater, Combination therapy, Recurrent) in China (Parenteral) (NCT06496373)